9 research outputs found
Setting and analysis of the multi-configuration time-dependent Hartree-Fock equations
In this paper we motivate, formulate and analyze the Multi-Configuration
Time-Dependent Hartree-Fock (MCTDHF) equations for molecular systems under
Coulomb interaction. They consist in approximating the N-particle Schrodinger
wavefunction by a (time-dependent) linear combination of (time-dependent)
Slater determinants. The equations of motion express as a system of ordinary
differential equations for the expansion coefficients coupled to nonlinear
Schrodinger-type equations for mono-electronic wavefunctions. The invertibility
of the one-body density matrix (full-rank hypothesis) plays a crucial role in
the analysis. Under the full-rank assumption a fiber bundle structure shows up
and produces unitary equivalence between convenient representations of the
equations. We discuss and establish existence and uniqueness of maximal
solutions to the Cauchy problem in the energy space as long as the density
matrix is not singular. A sufficient condition in terms of the energy of the
initial data ensuring the global-in-time invertibility is provided (first
result in this direction). Regularizing the density matrix breaks down energy
conservation, however a global well-posedness for this system in L^2 is
obtained with Strichartz estimates. Eventually solutions to this regularized
system are shown to converge to the original one on the time interval when the
density matrix is invertible.Comment: 48 pages, 1 figur
A multiproxy approach to reconstruct the envronmental changes along the Eurasian continental margin over the last 150.000 years
Allogeneic stem cell transplantation for mantle cell lymphomaâupdate of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell transplantation (alloSCT) is associated with a higher early mortality, but can cure MCL. To investigate alloSCT for therapy of MCL, we conducted two prospective trials for de novo MCL (OSHO#74) and for relapsed or refractory MCL (OSHO#60). Fifteen and 24 patients were recruited, respectively. Induction was mainly R-DHAP alternating with R-CHOP. Conditioning was either Busulfan/Cyclophosphamide or Treosulfan/Fludarabin. Either HLA-identical siblings or matched-unrelated donors with not more than one mismatch were allowed. ATG was mandatory in mismatched or unrelated transplantation. Progression-free survival (PFS) was 62% and overall survival (OS) was 68% after 16.5-year follow-up. Significant differences in PFS and OS between both trials were not observed. Patients below 56 years and patients after myeloablative conditioning had a better outcome compared to patients of the corresponding groups. Nine patients have died between day +8 and 5.9 years after SCT. Data from 7 long-term surviving patients showed an excellent Quality-of-life (QoL) after alloSCT. AlloSCT for MCL delivers excellent long-term survival data. The early mortality is higher than after autoSCT; however, the survival curves after alloSCT indicate the curative potential of this therapy. AlloSCT is a standard of care for all feasible patients with refractory or relapsed MCL and should offer to selected patients with de novo MCL and a poor risk profile. For defining the position of alloSCT in the therapeutic algorithm of MCL therapy, a randomized comparison of autoSCT and alloSCT is mandatory
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011
Background
Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients.
Methods
Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival.
Results
The number of annually documented cases increased by 53.2% between 2002 (Nâ=â4 779) and 2011 (Nâ=â7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97â0.97), sex (OR 1.18, 95% CI 1.11â1.25), date of diagnosis (OR 1.05, 95% CI 1.04â1.06), âdiagnosis during screeningâ (OR 3.24, 95% CI 2.50â4.19) and place of residence (OR 1.23, 95% CI 1.16â1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8â83.9%).
Conclusions
No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis
Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.
Additional file 4: Table S3. of Tumour stage distribution and survival of malignant melanoma in Germany 2002â2011
Relative 5-year survival of malignant melanoma patients diagnosed between 2002 and 2011, overall (UICC 0-IV, X) (Nâ=â60 672) and for patients with invasive tumours (UICC I â IV, X) stratified by age, sex, UICC stage, âdiagnosis during screeningâ and place of residence (Nâ=â49 351) (DOCX 39 kb
Additional file 3: Table S2. of Tumour stage distribution and survival of malignant melanoma in Germany 2002â2011
Malignant melanoma patients aged 35Â years and above by age at diagnosis, sex, UICC stage, year of diagnosis, place of residence and âdiagnosis during screeningâ, Nâ=â34 739 (UICC 0 and X excluded) (DOCX 40 kb